To The Moon

📊 Market Recap

As of October 31, 2026 (ET), Moderna, Inc. ('MRNA') closed at $221.72, down -0.47% from the previous session's $222.76. The stock remains roughly 12.9% below its 52-week high of $254.48, while still up more than 650% year-to-date. The session's range of $217.22 to $227.81 shows fading selling pressure after the sharp October 23 plunge on the melanoma vaccine data leak, with buyers stepping in near the $217 area.

🚀 Key Drivers

• Cancer Vaccine Data Leak Fallout: The early leak of INTerpath-001 Phase III data triggered a record one-day drop of over 26% intraday, but the stock stabilized as Merck and Moderna confirmed full results would be formally released.
• ESMO Catalyst Ahead: The upcoming ESMO meeting and the release of complete Phase III data for the personalized mRNA cancer vaccine combined with Keytruda remain the central narrative and the key event risk for near-term direction.
• Index Inclusion Momentum: Moderna's recent addition to the Nasdaq-100 has reinforced passive fund demand and helped absorb selling pressure during the recent correction.

🎯 Price Outlook

Short-Term Upside/Downside Probability

Medium-Term Upside/Downside Probability

Key Price Zones

(The above forecast is generated by AI and is for reference only; it does not constitute any form of investment advice, trading guidance or return commitment.)

1. Technical Analysis 📈

Volume: Trading volume reached 8.9889 million shares with a volume ratio of 0.57, indicating reduced participation and a consolidation-like structure rather than a decisive breakout.

MACD: DIF (10.51) remains below DEA (13.60), with the histogram at -6.18. The negative MACD still reflects bearish momentum, but the histogram has narrowed for three consecutive sessions, suggesting the downtrend is losing force.

RSI: The 6-day RSI stands at 56.91 and the 12-day RSI at 56.78, both recovering from oversold territory and now in a neutral-to-positive zone, leaving room for further upside without being overbought.

2. Key Price Levels 🎯

Primary Support: $217.22 (recent intraday low). A decisive break below this level would signal renewed downside pressure toward $210.

Strong Resistance: $231.27 (near-term resistance). A close above this level would open the path toward the $235–$240 supply zone.

Immediate Pivot: $220.53 (session open area). Holding above $220 on a closing basis keeps the short-term bias tilted to the upside.

3. Valuation Perspective 💰

Moderna trades at a price-to-sales ratio of 39.73 and a negative TTM P/E of -27.69, while the forward P/E remains deeply negative at -26.46. Both metrics are far above historical norms for established biopharma companies and reflect heavy reliance on future mRNA cancer vaccine revenue. The price-to-book ratio of 13.09 further underscores the market's aggressive growth assumptions despite current losses.

4. Analyst Targets 🎯

A total of 19 institutions cover Moderna, with an average target price of $143.15, well below the current market price. Ratings are skewed toward caution: 1 Strong Buy, 4 Buy, 16 Hold, 3 Underperform, and 1 Sell. The wide gap between the average target and the actual price suggests analysts think the stock has already priced in a substantial portion of its long-term potential.

5. Weekly Outlook 🔮

The stock is expected to fluctuate between $217 and $231 over the next one to two weeks as the market digests the data leak shock. A breakout above $231 could target $235 and then $240; a breakdown below $217 may trigger a pullback toward $210 and the psychologically important $200 level.

Key events to watch in the coming 1–2 weeks:

• Release of complete INTerpath-001 Phase III data for Moderna and Merck's personalized melanoma cancer vaccine, the most important near-term catalyst.
• ESMO meeting presentations and any additional commentary from company management on the cancer vaccine pipeline.
• Broader biotech sentiment and Nasdaq-100 index fund flows following Moderna's recent inclusion.

Risk Disclaimer ⚠️

This content is for informational purposes only and does not constitute investment advice. Stock markets carry risk, and investors should exercise caution. Moderna's current valuation depends heavily on successful clinical development and commercialization of its cancer vaccine pipeline; any negative data readout or regulatory setback could trigger a significant share price correction.